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Glioblastoma (GB) represents the most common and aggressive form of malignant primary brain 20 
tumour associated with high rates of morbidity and mortality. In this study we considered the potential 21 
use of idebenone, a Coenzyme Q10 analogue, as a novel chemotherapeutic agent for GB. On two GB 22 
cell lines, U373MG and U87MG, idebenone decreased the viable cell number and enhanced the 23 
cytotoxic effects of two known anti-proliferative agents: temozolomide and oxaliplatin. Idebenone 24 
also affected the clonogenic and migratory capacity of both GB cell lines, at 25 M and 50 M, a 25 
concentration equivalent to that transiently reached in plasma after oral intake that is deemed safe for 26 
humans. p21 protein expression was decreased in both cell lines indicating that idebenone likely 27 
exerts its effects through cell cycle dysregulation and this was confirmed in U373MG cells only by 28 
flow cytometric cell cycle analysis which showed S phase arrest. Caspase-3 protein expression was 29 
also significantly decreased in U373MG cells indicating idebenone-induced apoptosis that was 30 
confirmed by flow cytometric Annexin V/PI staining. No major decrease in caspase-3 expression was 31 
observed in U87MG cells nor apoptosis as observed by flow cytometry analysis. Overall, the present 32 
study demonstrates that idebenone has potential as an anti-proliferative agent for GB by interfering 33 
with several features of glioma pathogenesis such as proliferation and migration and hence might be a 34 
drug that could be repurposed for aiding cancer treatments. Furthermore, the synergistic combinations 35 
of idebenone with other agents aimed at different pathways involved in this type of cancer is 36 
promising.  37 
38 




Glioblastoma (GB) represents the most common and aggressive form of malignant primary brain 43 
tumour and is associated with high rates of morbidity and mortality (1). Despite the substantial 44 
advances in neurosurgical techniques in combination with radio/chemotherapy, the median overall 45 
survival time of GB patients remains only approximately 8-15 months and it has not changed 46 
significantly over the past four decades (2).  This is reflected in the limited success of recent phase III 47 
clinical trials making treatment of GB one of the greatest challenges in neuro-oncology (3). In the 48 
attempt to improve treatment outcomes of GB patients and to increase their survival rate and quality 49 
of life, a diverse range of therapeutic strategies are being explored. These include immunotherapy, 50 
nanoparticles encapsulating anti-cancer agents, gene therapy along with the substantial need for 51 
exploring and developing new, effective and safe chemotherapeutic agents (4). An important 52 
prerequisite for the success of any drug for this disease is that of crossing the blood brain barrier 53 
(BBB) even though this barrier is disrupted at the brain-tumour interface (5). One such compound that 54 




dogs is idebenone (IDE) (6,7). IDE is exploited currently by the pharmaceutical industry to treat age-56 
related cognitive disorders including Alzheimer’s disease due to its powerful antioxidant properties 57 
(8,9), and it has recently been used with success for treatment of several mitochondrial related-58 
neuromuscular disorders, especially Leber’s hereditary optic neuropathy and Friedrich’s ataxia (10-59 
14). Chemically, IDE is structurally similar to the naturally occurring Coenzyme Q10 (Fig. 1), in that 60 
both possess a benzoquinone moiety involved in electron transport, but their hydrophobic tails differ 61 
in length and composition. The shorter tail of IDE seems to be the ideal length for favouring 62 
partitioning into the mitochondrial membrane and for a better BBB permeation compared to 63 
Coenzyme Q10 (15). It therefore, has a more favourable pharmacokinetic profile and, in some cases, is 64 
considered a better therapeutic agent than its natural analogue (16,17).  65 
Recent research suggests that IDE may also have potential use as an anti-cancer agent. Tai et al. 66 
studied the effect of IDE on human dopaminergic neuroblastoma SHSY-5Y cells demonstrating that 67 
concentrations > 25 μM were cytotoxic and that the mechanism of cell death was apoptotic in nature 68 
(18). Seo et al. showed that in PC-3 prostate cancer cells and in CFPAC-1 pancreatic ductal 69 
adenocarcinoma cells, IDE reduced cell proliferation, inhibited cell migration and induced apoptosis 70 
by inhibiting anoctamin 1 (ANO1), a calcium activated chloride channel which is significantly 71 
increased in various tumours (19). These are the only two studies that have specifically investigated 72 
the effects of IDE on human cancer cells to date. Both demonstrated that it was effective, highlighting 73 
the potential this compound has as an anti-proliferative agent if studied more extensively on other 74 
cancer cell lines. For these reasons, IDE could be an interesting candidate for investigation against 75 
GB. 76 
Therefore the aim of the study was to investigate the influence of IDE on growth, regulation and 77 
migration of two human GB cell lines, U87MG and U373MG, in order to determine whether IDE 78 
might be a potential new anticancer agent. 79 
 80 
Materials and Methods 81 
Cell Culture and Reagents 82 
Idebenone (Tocris, UK) and Temozolomide (Sigma, USA) were both prepared as a 100 mM stock 83 
solution in dimethyl sulphoxide (DMSO), whereas Oxaliplatin (Tocris, UK) was prepared as a 10 mM 84 
stock solution in sterile water. They were all aliquoted and stored at -20 °C until use. The following 85 
antibodies were purchased from different sources: anti-p21/WAF1/Cip74 (#05-655, EMD Millipore, 86 
USA), anti--Actin (#Ab119716, Abcam, USA), anti-Casp3 (#HPA002643, Sigma, USA), anti-rabbit 87 
and anti-mouse IgG-HRP (#sc-2004, #sc-2005 respectively, Santa Cruz Biotechnology, USA). All 88 
other analytical grade chemicals were purchased from Sigma-Aldrich (USA).  89 
Human glioblastoma cell lines, U373MG and U87MG were procured from ECACC and are 90 




were cultured in Eagle’s minimum essential medium (MEM) supplemented with 10% fetal bovine 92 
serum (FBS), 100 units/mL penicillin, 100 g/mL streptomycin, 2 mM L-glutamine, under standard 93 
cell culture conditions (37 °C, 5% CO2, humidified atmosphere), passaged every 4/5 days and used 94 
within 8-20 passages. Prior to each experiment, they were seeded in appropriate plates/dishes at a 95 
seeding density of 2.4 x 104 cells/cm2 and treated according to each assay protocol. Appropriate 96 
controls were included throughout including the use of maximum concentration of vehicle that the 97 
cells were exposed to which did not exceed 0.05% for DMSO. This concentration did not cause any 98 
observable harmful effects on the cells based on cell morphology and cell growth. 99 
 100 
MTT and Trypan Blue exclusion assays and cell growth analysis 101 
Cells were seeded onto 96-well plates and allowed to grow for 48 h after which medium was 102 
replaced with that containing increasing concentrations of the chosen drugs or their combinations (100 103 
L final volume). For combination studies, the drugs were added simultaneously. After different 104 
exposure times (24-72 h), the effects of the compounds on cell viability was determined using the 3-105 
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (21). Ten μL of MTT 106 
solution in PBS (5 mg/mL) were added to each well and cells were incubated for a further 3 h at 37˚C. 107 
Medium was removed and replaced with 100 μL of DMSO to solubilize the crystals. The optical 108 
density of each well was determined at 570 nm on a microplate reader (Tecan SunriseTM) and viable 109 
cell count was assessed as a percentage relative to untreated cells. The IC50 values for each drug were 110 
calculated using GraphPad Prism 7 XML Project (GraphPad Software Inc. San Diego, USA). 111 
For cell growth analysis, cells were seeded in 35 mm cell culture dishes in 2 mL medium in 112 
duplicate and allowed to grow for 48 h, after which medium was replaced with that containing 113 
different concentrations of IDE and incubated for a further 48 h. Cells were then harvested by 114 
trypsinization, resuspended in 1 mL PBS and counted on an automated cell counter (Beckman Z2 115 
Coulter Particle Count and Size Analyzer). For determining the number of dead/dying cells, the 116 
trypan blue exclusion dye assay was used. The same procedure as described above for cell growth 117 
analysis was followed, except that cells were counted under light microscopy on a hematocytometer 118 
after staining with 0.1 % trypan blue solution in PBS at a 10x dilution factor. The number of 119 
dead/dying cells (stained) was assessed as a percentage of the total cell number for each treatment. 120 
 121 
Colony formation assay 122 
The colony forming assay was performed to evaluate the effects of IDE on the clonogenic capacity 123 
of U373MG and U87MG cells. Cells were seeded in 60 mm cell culture dishes in duplicate (200 and 124 
400 cells respectively/2.5 mL medium) and after 4 h (to allow cells to attach), 2.5 mL of appropriate 125 
concentrations of IDE were added in order to reach the desired final concentrations in 5 mL. Cells 126 




fixed and stained with 2 mL 0.5% crystal violet solution in 50% methanol for 30 min, rinsed again 128 
carefully with tap water and left to dry in normal air at room temperature. Colonies containing more 129 
than 50 cells were counted as representative of clonogenic cells under a Carl Zeiss
TM
 Stemi 2000-C 130 
stereo microscope. The surviving fraction which is the number of colonies that arise after cell 131 
treatment expressed in terms of plating efficiency, was determined according to the formula reported 132 
in Franken et al. (22): ((no. of colonies formed after treatment)/(no. of cells seeded x plating 133 
efficiency of the control)). 134 
 135 
Cell migration assay 136 
The effect of IDE on cell migration was assessed using the scratch/wound assay as previously 137 
developed by Valster et al. (23). The cells were grown to confluence in a 6-well cell culture plate for 138 
72 h, washed twice with medium without FBS and a scratch was performed with the tip of a sterile 139 
200 L pipette tip to create a defined, uniform scratch in the centre of the well. Medium with 140 
suspended cells was removed and replaced with medium containing 0.5% FBS with or without 141 
different concentrations of IDE. Closure of the wounds by migrating cells was observed under a 142 
digital inverted microscope (Evos XL, AMG), right after the scratch and at 24 and 48 h of incubation 143 
and images were taken in the same field by marking the wells underneath. An average of six 144 
images/well/time point were taken and the gap surface area of the wound was analysed using Image J 145 
software and expressed as the percentage of the area at time 0 h. 146 
 147 
Western immunoblotting analysis 148 
Cells were seeded onto 60 mm diam. dishes in duplicate, and after 48 h, the medium was replaced 149 
with different concentrations of IDE and incubated for a further 48 h. Cells were then harvested and 150 
the lysates in RIPA buffer were stored at -80 °C. After thawing, brief vortexing and centrifugation at 151 
16 000 g for 15 min at 4 °C, the protein concentration was determined on the supernatant using the 152 
BCA protein assay according to the manufacturer’s instructions (Pierce BCA Protein assay kit, 153 
Thermo Scientific, USA). Samples containing equal amounts of protein were separated by 12% SDS-154 
PAGE and the proteins were transferred overnight at 4 °C on PVDF membranes and probed for the 155 
proteins of interest as previously reported (24). The primary antibodies were used at the following 156 
dilutions: anti-p21 (1:750), anti-pro-caspase3 (1:500), anti--actin (1:5000), while the secondary ones 157 
were 1:7000 for anti-rabbit and 1:3000 for anti-mouse HRP-labelled antibodies. The protein bands 158 
were detected using an enhanced chemiluminescent substrate (Supersignal West Dura, Thermo 159 
Scientific, USA) and captured on a Genoplex VWR Bio imager (VWR, USA). Protein bands were 160 
quantified using Image J software and the data are reported as the percentage of intensity of the band 161 





Flow cytometry analyses  164 
Cells were seeded onto 6-well plates and allowed to grow for 48 h after which medium was 165 
replaced with that containing different concentrations of IDE or camptothecin (1 M) used as positive 166 
control, and incubated for 24 h. Cells were then harvested by trypsinization and combined with 167 
floating cells collected from the medium, pelleted, and washed with PBS. For Annexin V/propidium 168 
iodide (PI) staining, the Annexin V-FITC Kit (Miltenyi Biotec, Germany) was used and the assay was 169 
performed according to the manufacturer’s protocol. Briefly, after washing cells with 1x annexin-170 
binding buffer, cells were resuspended in 100 L 1x annexin-binding buffer to which 10 L of 171 
Annexin V-FITC was added and incubated for 15 min at room temperature. Cells were then washed 172 
with 1 mL 1x binding buffer, and to the cell pellet resuspended in 500 L of this same buffer, 5 L of 173 
PI solution was added directly before measurement on a BD Fortessa flow cytometer (BD Bioscience, 174 
USA). Emission of Annexin V-FITC was detected at 530 nm and PI fluorescence was collected at 175 
670/14 nm with excitation at 488 nm. For the detection of apoptotic events, the percentage of the 176 
population was evaluated on single cells, which are positive for AV-FITC or PI, using the FlowJo-177 
V10 analysis software (FlowJo LLC, USA).  178 
Cell cycle analysis was performed by measuring the changing amount of DNA associated with 179 
each phase of the cell cycle. Cellular DNA was labelled with DNA binding fluorochrome and 180 
subsequent fluorescence was measured to determine the relative DNA content and cell cycle position. 181 
Briefly, after harvesting the cells as described above, the cell pellets were fixed with 1 mL 70% 182 
ethanol overnight at -20°C. Cells were then pelleted at 2,500 g/5 min and washed with 1 mL 183 
phosphate-citrate buffer (0.2 M Na2HPO4, 0.1 M citric acid, pH 7.8). The cell pellet was resuspended 184 
in 100 L RNase A (100 g/mL in PBS) and incubated for 15 min at 37 °C before adding 400 L of 185 
PI solution (50 g/mL in PBS) directly to it. After 1 h incubation in the dark at room temperature, the 186 
DNA content was analysed as PI fluorescence emission at 610 nm using the 561 nm laser on the BD 187 
Fortessa analyser. Cell cycle phases were evaluated using the cell cycle module of the analysing 188 
software FlowJo-V10. 189 
 190 
Statistical Analysis 191 
All experiments were repeated independently at least three times. IC50 values of compounds were 192 
analysed using GraphPad Prism 7 using non-linear sigmoidal curve fitting with the normalized 193 
response. In the case of Oxaliplatin, the Excel add-in ed50v10 was used as this gave better curve 194 
fitting for obtaining the IC50. Statistical differences were analysed using one-way ANOVA followed 195 
by Dunnett’s post-hoc analysis or Student’s t-test using GraphPad Prism 7 XML Project (GraphPad 196 
Sofware Inc. San Diego, USA). Significant differences were defined as p < 0.05. Excess Over Bliss 197 




according to Liu et al. (25), where an EOB score > 0 is considered synergism, = 0 199 
independent/additive, < 0 antagonism. 200 
 201 
Results 202 
Idebenone decreased viable cell number in glioblastoma cells and enhanced the anti-tumour 203 
effects of Temozolomide and Oxaliplatin 204 
The effects of increasing concentrations of IDE on the viable cell number of U373MG and 205 
U87MG cells were determined using the MTT assay (Fig. 2A,B). At concentrations of IDE > 20 M, 206 
a statistically significant decrease in viable cell number was observed for both cell lines at almost all 207 
exposure times compared to untreated controls. The half maximal inhibitory concentrations (IC50) at 208 
48 h were 84.5±5.2 M for U373MG and 74.4±2.7 M for U87MG. At longer exposure times, IDE 209 
became increasingly toxic with less than 30% of viable cells remaining after 96 h exposure at 50 M 210 
(IC50 for U373MG at 72 and 96 h are 31.3±1.9 M and 41.1±3.1 M respectively, while those for 211 
U87MG are 38.7±1.7 M and 26.6±1.8 M respectively). 212 
In order to compare the effects of IDE with known anti-cancer agents, cells were also exposed to 213 
Temozolomide (TMZ) and Oxaliplatin (OX) for 48 h (Fig. 2C,D).  Exposure to oxaliplatin lead to a 214 
statistically significant decrease in U87MG viable cell number compared to untreated cells at 215 
concentrations > 250 M while in U373MG cells this was observed starting from 350 M (Fig. 2C). 216 
The IC50 for U87MG and U373MG are 342.4±2.4 M and 476.8±12.4 M respectively, suggesting 217 
that U373MG cells are more resistant to OX. However, both these values are about five times higher 218 
compared to those obtained for IDE which are > 70 M for both cell lines. TMZ had little effect in 219 
both cell lines (Fig. 2D). The IC50 was > 500 M for both cell lines which is seven times greater than 220 
that of IDE. Thus under our experimental conditions, IDE exhibits greater toxicity than both known 221 
anti-cancer agents alone and U373MG cells are more resistant to these drug treatments than U87MG 222 
cells. Others have also reported that U373MG cells are more resistant to drug treatment which is 223 
consistent with our data (26,27).  224 
Since combining drugs is one of the major strategies used for improving clinical outcomes of GB 225 
(28), we explored whether IDE could modulate the effects of TMZ or OX. In the case of U87MG 226 
cells, the combination of IDE and OX lead to a greater decrease in cell viability than either IDE or 227 
OX alone. However, the results of EOB analysis reported in Fig. 3 suggest that this combination does 228 
not have impressive synergism since all values are less than 0.1. In U373MG cells, the combination of 229 
50 M IDE and OX also lead to a greater decrease than OX alone, but not to IDE alone (Fig. 3A,B). 230 
The co-presence of OX in this case seems to increase the number of viable cells compared to IDE 231 
alone. In fact, this combination appears to have an antagonistic effect according to EOB analysis. 232 




viability was also observed than when either were used alone in both cells lines (Fig. 3C,D), 234 
indicating a synergistic effect, albeit unimpressive, as found by EOB analysis.  235 
 236 
Idebenone inhibited growth of glioblastoma cells and affected their clonogenic and migratory 237 
capacity 238 
To determine the effects of IDE on cell growth, three concentrations corresponding to a low, 239 
medium and relatively high dose (10, 25, 50 M) of IDE were chosen based on the results reported in 240 
Fig. 2A,B (48 h). There was a decrease in total cell number for both cell lines with increasing 241 
concentrations of IDE (Fig. 4). In the case of U373MG cells, IDE appears to have a cytostatic effect, 242 
especially at 50 M since the cell number in its presence after 48 h incubation was almost identical as 243 
before IDE addition at time 0 (no growth). Instead for U87MG cells, IDE resulted more growth 244 
inhibitory since the cell number was reduced after IDE addition but always higher than the starting 245 
cell number. In the presence of IDE there was also a modest increase in trypan-blue positive staining 246 
indicating increased cell death in the presence of 25 and 50 M IDE after 48 h (Table 1). This 247 
increase is consistent with the trend observed with the MTT assay. 248 
The effects of IDE on cell survival were also assessed. Treatment of glioblastoma cells with IDE 249 
reduced the surviving fraction in a dose-dependent manner. After the two-week incubation period 250 
hardly any colonies were observed in cells treated with 50 M IDE (Fig. 5A,B). Since the number of 251 
colonies is a reliable indicator of the survival potential of these cells, the results indicate that IDE at 252 
concentrations > 25 M drastically reduces the ability of glioblastoma cells to survive.  253 
Glioblastomas are known to be highly invasive and infiltrative tumours which are hallmarks of this 254 
type of disease, therefore the possible anti-migratory effect of IDE using the wound healing assay was 255 
also investigated (29,30). In untreated cells, after 24 h and 48 h cells migrated into the wound gap 256 
reducing its surface area (Fig. 6A). In the presence of 10 and 25 M IDE however, cell migration 257 
diminished by 45% and 65% respectively for U373MG cells and by 5% and 34% for U87MG cells 258 
respectively, at 24 h (Fig. 6B,C). At 48 h, IDE at both concentrations and in both cell lines 259 
significantly reduced cell migration compared to the untreated control at the same time point. The 260 
U87MG cells were more migratory than U373MG cells in accordance with the observation of others 261 
on these two cell lines (31,32). 262 
 263 
Idebenone reduced the expression of caspase-3 and p21 inducing apoptosis and cell-cycle arrest 264 
The next question was does IDE induce the effects observed through cell cycle dysregulation 265 
and/or apoptosis induction?  To examine this, the expression of p21 and caspase-3 respectively, were 266 
examined by western immunoblotting (Fig. 7). Under our experimental conditions IDE does not seem 267 
to exert its effects via apoptosis, at least not in U87MG cells. In these cells, caspase-3 is more 268 




control. This was also confirmed by flow cytometry analysis (Fig. 8A,B) using dual staining with 270 
Annexin V/PI where no appreciable differences were observed between the control and IDE treated 271 
cells. Camptothecin used as positive control, did however induce apoptosis as can be observed by the 272 
significant increase in cells in late apoptosis compared to the control. In U373MG cells a decline in 273 
caspase-3 protein expression was evident and significant at 50 M IDE (Fig. 7B). This finding was 274 
confirmed by flow cytometry (Fig. 8C,D) which showed that IDE at 25 M and 50 M significantly 275 
increased the percentage of early apoptotic cells by almost 2-fold compared to the untreated control as 276 
well as the percentage of cells in late apoptosis at the highest concentration. From the results shown in 277 
Fig. 7A and 7C, it also appears that IDE affects the cell cycle since in both cell lines there was a 278 
decreasing trend in expression of p21 with increasing concentration of IDE. This is especially the case 279 
in U373MG cells which is consistent with the flow cytometry data showing single staining with PI for 280 
DNA cell cycle content and distribution (Fig. 9A,B). In this cell line, a significant dose-dependent 281 
decrease in cell population in the G1 phase (54% and 42% at 25 M and 50 M IDE respectively vs 282 
66% of control) and 1.5 to 2-fold increase in the S phase (31% and 41% at 25 M and 50 M IDE 283 
respectively vs 21% of control) were observed in the presence of IDE (Fig. 9B). In U87MG cells, as 284 
observed for caspase-3, p21 was more expressed compared to U373MG cells. However, despite the 285 
significant decrease in p21 expression in these cells at 50 M, the DNA distribution analysed by flow 286 
cytometry revealed no apparent changes in the presence of IDE in three independent experiments 287 
(results not shown). 288 
 289 
Discussion 290 
The main purpose of this study was to investigate the potential anti-cancer effect of IDE on two 291 
human glioblastoma cells lines. GB is one of the most resistant tumours to conventional cytotoxic 292 
therapies therefore current studies concentrate on the development of novel agents for use either alone 293 
or in combination with standard chemotherapy and radiotherapy. In this study, we demonstrate that 294 
IDE decreased cell viability in a time and concentration dependent manner and that it was cytotoxic at 295 
concentrations similar to those reported by others on both human and non-human cancer cells 296 
(18,19,33,34). Furthermore, in a separate study IDE had no effect on a normal cell line consisting of 297 
colonocytes (CCD841CON) whereas it proved to be cytotoxic in a colorectal cancer cell line 298 
(SW480) (results not shown). Interestingly, when IDE was co-administered with the two well-known 299 
anti-cancer agents, TMZ and OX, a greater decrease in cell viability was observed in both cell lines, 300 
especially with TMZ. This improved effect resulted marginally synergistic. Since IDE appears to 301 
enhance the cytotoxic effects of TMZ, this novel combination for GB therapy merits further 302 
investigation, especially as combinations of other drugs and natural compounds with TMZ are being 303 
explored continuously (27,31,35-40). OX has been occasionally used for treating GB but limited due 304 




have been indications recently for repurposing platinum-based chemotherapies for multi-modal 306 
treatment of GB. Hence it could be more widely used for GB treatment in the future (42). Besides this 307 
aspect, IDE also proved to be more potent than both cytotoxics, with IC50 value at least five times 308 
lower than those of the known drugs.  The reduced number of colonies in the gold standard colony 309 
forming assay, provided further evidence of the growth inhibitory and hence survival effects of IDE. 310 
To the best of our knowledge, this is the first report showing the ability of IDE to hamper with cell 311 
survival in the long-term.  In the context of preventing recurrence this is important, as the capacity for 312 
unlimited proliferation of all stem cells must be eradicated. In this study we also established that IDE 313 
inhibits cell migration as previously observed in prostate cancer cells (19). This anti-314 
migratory/metastatic effect of IDE on GB cells could help to contain spreading of a GB tumour in 315 
vivo. 316 
In the attempt to address the possible mechanisms underlying the effects displayed by IDE on 317 
glioma cells, we found that apoptosis is probably not a major pathway responsible for the above 318 
outcomes, at least not in U87MG cells where no major decline in pro-caspase-3 was observed nor was 319 
there any indication from the flow cytometric data. Caspase-3 belongs to the executioner family of 320 
cysteine-aspartic acid proteases (caspases), and plays a dominant role in the hallmark caspase cascade 321 
characteristic of the apoptotic pathway (43). Upon activation it is cleaved into its active 17 kDa and 322 
12 kDa fragments which leads to a concomitant decrease in intensity of the uncleaved band at 32 kDa 323 
during immunoblot analysis. This could explain the dose-dependent decrease in protein expression 324 
observed in U373MG cells in the presence of IDE. Indeed, in U373MG cells IDE appears to induce 325 
modest apoptosis as also confirmed by Annexin/PI staining analysis using flow cytometry.  These 326 
results are in accordance with two previous reports on the direct effects of IDE on cancer cells which 327 
both describe an apoptotic effect of IDE (18,19). Seo et al. attribute their observations to the fact that 328 
IDE blocks the ANO1 calcium-chloride channel, but it has no effect on cancer cells which do not 329 
express ANO1 (19). However, in U87MG cells we failed to observe evidence of IDE-induced 330 
apoptosis and this could be due to the p53 status of the two cell lines. p53 is a well-known tumour 331 
suppressor protein which when active, induces a number of genes linked to diverse functions such as 332 
cell cycle regulation, DNA repair mechanisms and those related to apoptosis (44). U87MG cells have 333 
a wild-type p53 gene but do not express the functional protein to any measurable extent because of 334 
Mdm2 overexpression which destabilizes it (45), whereas U373MG cells have a mutant p53 gene 335 
(44). Lack of p53 activity in U87MG cells could thus prevent the induction of p53-dependent 336 
apoptosis whether IDE is present or not, explaining our results. In the case of U373MG, dysfunctional 337 
p53 activity due to the mutated gene would make these cells more sensitive to high concentrations of 338 
IDE which could then respond by apoptosis, as indicated by the decreased expression of pro-caspase-339 
3 at 50 M IDE and by the flow cytometric analysis. This divergent apoptotic response to IDE 340 
possibly due to the p53 status of the two cell lines, is similar to that described by Datta et al. on the 341 




in U87MG cells compared to U373MG cells may also reflect this different status, similarly to the 343 
observations by Ravizza et al. for p21 (27). 344 
It is more likely that under our experimental conditions, IDE exerts its anti-proliferative effects by 345 
interfering with cell cycle regulation, since in both cell lines a decline in protein expression of the 346 
cyclin-dependent kinase (CDK) inhibitor, p21 (known as p21WAF1/Cip1) was evident especially at 347 
high concentrations. This protein is uniquely positioned in the cell cycle to function as both a sensor 348 
and an effector of multiple anti-proliferative signals in response to a variety of cellular and 349 
environmental signals to promote tumour suppressor activities, both dependently and independently 350 
of the classical p53 tumour suppressor pathway. Usually, it is assumed that p21 downregulation or 351 
repression increases cell cycle progression and proliferation due to disinhibition of cyclin/cdk 352 
complexes (47). However, this is not always the case as indicated by several reports in which p21 353 
functions as a positive cell cycle regulator. Indeed, in U373MG cells we observed using flow 354 
cytometry, a dose-related increase in cell population in the S phase and a concomitant decrease in 355 
cells in the G1 phase of the cell cycle, suggesting that IDE is responsible for accumulation of cells in 356 
S phase.  A similar S phase arrest concomitant with p21 downregulation has also been observed by 357 
others in human cells under different treatment regimes (48-50). During S phase, replication can cease 358 
in response to DNA damage or stress to the replication process.  However, while the former response 359 
induces arrest through different mechanisms involving ATM protein kinases and invoking p53 and 360 
p21 response, the response to replicative stress arrests all cells regardless of p53 status and is not 361 
accompanied by p21 induction (51). Since we do not observe IDE-induced p21 in GB cells, we expect 362 
that IDE is affecting them mainly through replicative stress. The correlation between reduced 363 
expression of p21 and impairment of cell proliferation as observed in our study has been shown in 364 
several cell models ranging from HaCaT keratinocytes (52), smooth muscle cells (53), endothelial 365 
cells (54), colon and liver cancer cells (55,56) exposed to different stimuli although the reason for this 366 
has not always been clarified. The mechanism by which IDE downregulates p21 in glioma cells 367 
remains to be elucidated. However, the evidence so far suggests that in U373MG cells, IDE-induced 368 
S-phase arrest is linked to p21 down-regulation and that this plays an important part in IDE-induced 369 
apoptosis. This is supported by the fact that in several systems p21 down-regulation has been shown 370 
to trigger apoptosis (57-59). In U87MG cells, despite observing p21 decrease in the presence of IDE 371 
at 50 M, we could not link this to any changes in DNA cell cycle distribution, suggesting that our 372 
observations are cell-line specific. These differential responses between the two cell lines may depend 373 
on their p53 status as recently reviewed by Georgakilas (60) who depicts p21 as an onco-suppressor 374 
or an onco-promotor depending on cell type, cellular localization, p53 status, and the type and level of 375 
genotoxic stress. The fact that IDE downregulates p21 expression in U373MG and U87MG cells 376 
which are p53-deficient/mutant, implies that IDE could repress the oncogenic potential of these cells 377 
via p21 inhibition. Repression of p21 by IDE could also explain the anti-migratory effect observed in 378 




induced by the inflammatory cytokine IL-20 (61). Further investigations are clearly required to 380 
understand mechanistically the effects of IDE observed in this research. 381 
Overall, the present study demonstrates that IDE has potential as an anti-proliferative agent for GB 382 
by interfering with several features of glioma pathogenesis such as proliferation and migration. The 383 
human safety of IDE is well-established and a daily dose of 60 mg/kg/day has been shown to reach a 384 
transient concentration in plasma equivalent to 29.6 M (62). This is a concentration close to those 385 
used in this study which were effective (25-50 M). Recently, the repurposing of existing drugs has 386 
attracted considerable attention (63) because it is advantageous, in time and cost saving. Therefore 387 
IDE, besides its current use in mitochondrial related-neuromuscular and neurodegenerative diseases, 388 
could be repurposed for aiding cancer treatments especially as it can cross the BBB. For example, its 389 
analogue Coenzyme Q10 has already been reported to be a promising candidate either alone or in 390 
combination for prevention and treatment of breast cancer (64). Atovaquone, another CoQ10 391 
analogue and an FDA-approved anti-malarial drug, is another example which is being considered for 392 
repurposing because of its anti-proliferative effect against MCF7 Cancer Stem-like Cells (65).The 393 
future treatment of malignant gliomas will likely involve synergistic combinations of agents aimed at 394 
different pathways in the molecular pathogenesis of this type of cancer. In this context, the results of 395 
the present study on IDE appear promising providing the preliminary experimental basis for exploring 396 
it further.  397 
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Legends to Figures 
573 
Figure 1. Chemical structure of Idebenone and the naturally occurring analogue, Coenzyme Q10. 574 
 575 
Figure 2. Effect of Idebenone, Oxaliplatin and Temozolomide on viable cell number of human 576 
glioblastoma cells. U373MG (A) and U87MG (B) cells were exposed to increasing concentrations of 577 
Idebenone for 48 h, 72 h or 96 h and cell-survival was assessed using the MTT assay. U373MG and 578 
U87MG cells were exposed to increasing concentrations of either Oxaliplatin (C) or Temozolomide 579 
(D) for 48 h and cell-survival was assessed using the MTT assay. The results are expressed as the 580 
percentage of viable cells compared to the control. Data are presented as mean ± SEM, of at least 24 581 
wells from at least four independent experiments (for Idebenone) and of at least 18 wells from at least 582 
three independent experiments for Temozolomide and Oxaliplatin. Statistics was performed using 583 
one-way Anova with Dunnett’s post-hoc analysis (* p<0.05 vs untreated). Dotted line is set at 50 % to 584 
show the IC50.  585 
 586 
Figure 3. Effect of Idebenone in combination with anti-cancer agents on viable cell number of human 587 
glioblastoma cells. Cells were treated with Idebenone (IDE), Oxaliplatin (OX), Temozolomide (TMZ) 588 
singularly and in combination at various concentrations for 48 h and viability was measured using the 589 
MTT assay. (A) U87MG cells in the presence of IDE and OX.  (B) U373MG cells in the presence of 590 
IDE and OX. (C) U87MG cells in the presence of IDE and TMZ. (D) U373MG cells in the presence 591 
of IDE and TMZ. The results are expressed as the percentage of viable cells compared to the control.  592 




Statistics was performed using one-way Anova with Dunnett’s post-hoc analysis (*p<0.05 vs OX or 594 
TMZ alone).  595 
The values reported above the bars for the combinations are the EOB score values. 596 
 597 
Figure 4. Effect of Idebenone on the growth of human glioblastoma cells. U373MG and U87MG cells 598 
were exposed to increasing concentrations of Idebenone for 48 h before counting using a Coulter 599 
Counter as described in the Methods section. Dotted line represents cell number prior to Idebenone 600 
addition (0 h) in both cell lines. Data are presented as mean ± SEM, n=3 independent experiments. 601 
Statistics was performed using Student’s t-test (*p<0.05 vs untreated).  602 
 603 
Figure 5. Effect of increasing concentrations of Idebenone on the clonogenic survival of human 604 
glioblastoma cells. U373MG and U87MG cells were seeded in 6 cm culture dishes at a density of 200 605 
cells/dish (U373MG) and 400 cells/dish (U87MG) and incubated for two weeks in the presence of 606 
increasing concentrations of Idebenone. (A) Surviving fraction of colonies analysed two weeks later 607 
after staining with crystal violet. (B) Clones produced by U373MG human glioblastoma cells only are 608 
shown since those produced by U87MG cells were only visible by light microscopy. The images are 609 
representative of at least 3 independent experiments each performed in duplicate. Data are presented 610 
as mean ± SEM, n=3 independent experiments. Statistics was performed using the Student’s t-test 611 
(*p<0.05 vs untreated).  612 
 613 
Figure 6. Effect of Idebenone on migration of human glioblastoma cells. For the wound healing assay, 614 
U373MG and U87MG cells were treated with different concentrations of Idebenone and the wound 615 
closure was quantified every 24 h post-wound. (A) Representative photomicrographs (x10) taken at 616 
time 0 h and at 48 h post-wounding of U373MG and U87MG cells grown in 6-well plates, incubated 617 
in the presence of 10 and 25 M Idebenone, are shown. Gap surface area of the scratch/wound were 618 
analysed using ImageJ software and are expressed as the % of the area of time 0 h in both cell lines 619 
(B) U373MG and (C) U87MG. Data are presented as mean ± SD, n=3 independent experiments. 620 
Statistics was performed using Student’s t-test (p<0.05), * vs respective 0 h, § vs untreated at same 621 
time point. 622 
 623 
Figure 7. Effect of Idebenone on expression of caspase-3 and p21 in human glioblastoma cells. 624 
Protein expression was analysed by immunoblotting. (A) p21 and Caspase-3 expression in control and 625 
treated cells, 48 h post-exposure to Idebenone (IDE). -actin was used as loading control. The images 626 
are representative of three independent experiments. Results on quantification of caspase-3 (B) and 627 
p21 (C) protein expression from three independent experiments using ImageJ software. Data are 628 





Figure 8. Annexin V-FITC/PI flow cytometric analysis of apoptosis in human glioblastoma cells. 631 
U373MG and U87MG cells were treated with different concentrations of Idebenone (IDE) or 1 M 632 
Camptothecin (CPT) for 24 h, harvested by trypsinization, stained with annexin V-FITC (AV) and 633 
propidium iodide (PI) and then subjected to flow cytometry and analysed. AV-PI-, live cells; AV+PI-, 634 
early apoptosis; AV+PI+, late apoptosis; AV-PI+, necrosis.  (A) Representative dot plots from one 635 
experiment are shown for U87MG cells. (B) Graph showing data collected for U87MG cells from 636 
‘AV+PI-, AV+PI+ quadrants’ from 3 independent experiments. (C) Representative dot plots from one 637 
experiment are shown for U373MG cells. (B) Graph showing data collected for U373MG cells from 638 
‘AV+PI-, AV+PI+ quadrants’ from 3 independent experiments. Data are presented as mean ± SEM, 639 
n=3. Statistics was performed using Student’s t-test (*p<0.05 vs control). 640 
 641 
Figure 9. Flow cytometric analysis of cell cycle parameters in human glioblastoma cells. U373MG 642 
and U87MG cells were treated with different concentrations of Idebenone (IDE) or 1 M 643 
Camptothecin (CPT) for 24 h, harvested by trypsinization, fixed, stained with propidium iodide (PI) 644 
and then subjected to flow cytometry and analysed for cell cycle DNA distribution. (A) 645 
Representative DNA content histograms from one experiment are shown for U373MG cells. G1 phase 646 
(darkest/purple fraction), S phase (lightest/yellow fraction), G2 (grey/green fraction). (B) Graph 647 
showing data collected for U373MG cells from the three different fractions of the histograms from 3 648 
independent experiments. Data are presented as mean ± SEM, n=3. Statistics was performed using 649 
Student’s t-test (*p<0.05 vs control). Data for U87MG cells are not shown as no differences were 650 






































Table 1: Number of dead/dying human glioblastoma cells in the presence of Idebenone. U373MG 
and U87MG cells were exposed to increasing concentrations of Idebenone for 48 h before the Trypan-
Blue exclusion assay was performed to determine the no. of dead/dying cells as described in the 
Methods section. The results are reported as the % of dead/dying cells over the total cell no. for each 
treatment. Data are presented as mean ± SD, n=3 independent experiments. Statistics was performed 
using the Student’s t-test (*p<0.05 vs untreated).  
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